Eric Schmidt, SandboxAQ chairman (Susan Walsh/AP Images)
June 22, 2023 02:18 PM EDTUpdated June 23, 07:18 AM
Deals

As­traZeneca, Sanofi turn to Al­pha­bet spin­out's AI and quan­tum tech­nolo­gies for drug dis­cov­ery

Zachary Brennan

Senior Editor

As part of its bio­phar­ma R&D ac­cel­er­a­tion ef­forts, an Al­pha­bet spin­out an­nounced to­day that it’s work­ing with As­traZeneca, Sanofi and oth­ers on drug dis­cov­ery and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times